The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease

The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease

Abstract The pathology of Parkinson’s disease (PD) is characterized by α-synuclein aggregation, microglia-mediated neuroinflammation, and dopaminergic neurodegeneration in the substantia nigra with collateral striatal dopamine signaling deficiency. Microglial NLRP3 inflammasome activation has been l...

Full description

Bibliographic Details
Main Authors:	Adrianne F. Pike, Ildikò Szabò, Robert Veerhuis, Luigi Bubacco
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-03-01
Series:	npj Parkinson's Disease
Online Access:	https://doi.org/10.1038/s41531-022-00293-z

Similar Items

Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
by: Adrianne F. Pike, et al.
Published: (2022-02-01)

Impaired dopamine metabolism in Parkinson’s disease pathogenesis
by: Anna Masato, et al.
Published: (2019-08-01)

Itaconate Attenuates Neuroinflammation and Exerts Dopamine Neuroprotection in Parkinson’s Disease through Inhibiting NLRP3 Inflammasome
by: Guoqing Sun, et al.
Published: (2022-09-01)

Distinct Molecular Mechanisms Underlying Potassium Efflux for NLRP3 Inflammasome Activation
by: Ziwei Xu, et al.
Published: (2020-12-01)

Squaramides enhance NLRP3 inflammasome activation by lowering intracellular potassium
by: Paula I. Seoane, et al.
Published: (2023-12-01)

Mechanistic basis for potassium efflux-driven activation of the human NLRP1 inflammasome
by: Rozario, Pritisha, et al.
Published: (2024)

Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome
by: Tan Zhang, et al.
Published: (2021-10-01)

The interplay between α-Synuclein and NLRP3 inflammasome in Parkinson's disease
by: Qianhui Huang, et al.
Published: (2023-12-01)

Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
by: Ranran Lu, et al.
Published: (2022-10-01)

Key Mechanisms and Potential Targets of the NLRP3 Inflammasome in Neurodegenerative Diseases
by: Yadi Guan, et al.
Published: (2020-07-01)

NLRP3 Inflammasome as a Therapeutic Target for Atherosclerosis: A Focus on Potassium Outflow
by: Yi-Jing Jin, et al.
Published: (2022-07-01)

The Convergence of Dopamine and α-Synuclein: Implications for Parkinson’s Disease
by: Danielle E Mor, et al.
Published: (2018-03-01)

A novel mechanism for NLRP3 inflammasome activation
by: Tan Zhang, et al.
Published: (2022-03-01)

The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis
by: Carol M. Artlett
Published: (2022-04-01)

Inhibiting the NLRP3 Inflammasome
by: Lina Y. El-Sharkawy, et al.
Published: (2020-11-01)

Molecular crosstalk between circadian clock and NLRP3 inflammasome signaling in Parkinson's disease
by: Jiahua Huang, et al.
Published: (2024-01-01)

The NLRP3 inflammasome is a potential mechanism and therapeutic target for perioperative neurocognitive disorders
by: Jiayue Li, et al.
Published: (2023-01-01)

Editorial: NLRP3 Inflammasome: Regulatory Mechanisms, Role in Health and Disease and Therapeutic Potential
by: Oleg V. Chernikov, et al.
Published: (2021-09-01)

NLRP3 inflammasome: the core mechanism and potential target of inflammatory response in Alzheimer's disease
by: Jian-quan SHI, et al.
Published: (2020-01-01)

Heat‐killed Lactobacillus murinus confers neuroprotection against dopamine neuronal loss by targeting NLRP3 inflammasome
by: Hong‐Xia Fan, et al.
Published: (2023-03-01)

Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors
by: Pritam Thapa, et al.
Published: (2023-04-01)

The NLRP3 Inflammasome: Role and Therapeutic Potential in Pain Treatment
by: Hana Starobova, et al.
Published: (2020-08-01)

The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney
by: Yang Gyun Kim, et al.
Published: (2019-11-01)

Contradictory Effects of NLRP3 Inflammasome Regulatory Mechanisms in Colitis
by: Kohei Wagatsuma, et al.
Published: (2020-10-01)

NLRP3 inflammasome in digestive diseases: From mechanism to therapy
by: Rui Qiang, et al.
Published: (2022-10-01)

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
by: Xiaoyan Zhan, et al.
Published: (2023-01-01)

The Significance of NLRP Inflammasome in Neuropsychiatric Disorders
by: Yao Shen, et al.
Published: (2022-08-01)

Vitamin D and the NLRP3 Inflammasome
by: Matthew Tunbridge, et al.
Published: (2020-11-01)

The NLRP3-Inflammasome in Health and Disease
by: Anna Perri
Published: (2022-10-01)

Targeting the NLRP3 Inflammasome in Glaucoma
by: Sophie Coyle, et al.
Published: (2021-08-01)

The NLRP1 inflammasome in skin diseases
by: Marc Burian, et al.
Published: (2023-02-01)

Role of the NLRP3 Inflammasome in Preeclampsia
by: Koumei Shirasuna, et al.
Published: (2020-02-01)

Spotlight on the NLRP3 inflammasome pathway
by: Groslambert M, et al.
Published: (2018-09-01)

Pharmacological Inhibitors of the NLRP3 Inflammasome
by: Ayesha Zahid, et al.
Published: (2019-10-01)

NLRP3 inflammasome in metabolic syndrome
by: Fang Wang, et al.
Published: (2021-04-01)

Regulation of NLRP3 Inflammasome by Phosphorylation
by: Nan Song, et al.
Published: (2018-10-01)

Naringenin Produces Neuroprotection Against LPS-Induced Dopamine Neurotoxicity via the Inhibition of Microglial NLRP3 Inflammasome Activation
by: Ce Chen, et al.
Published: (2019-05-01)

Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention
by: Jiayu Zhang, et al.
Published: (2023-10-01)

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
by: Tao Liang, et al.
Published: (2022-02-01)

Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer
by: Gulcin Tezcan, et al.
Published: (2021-02-01)